Biochemical modelling to develop novel antibiotics

When interrogating our models, say by reducing the amount of a substrate in the system, we can accurately map the reaction across the whole cellular biochemistry mechanistically. This means we fully understand how the cell will be impacted, and if it can bypass inhibition. And most importantly of all, how it will do that.

N.A.

Our models allow us to accurately map cellular biochemistry at extremely high levels of resolution, which we use to identify the best drug targets whilst also confirming that cells cannot bypass their inhibition. We have identified a number of novel antimicrobial drug targets, with a full understanding of the biochemical impact of target inhibition, meaning a higher chance of development success, and a lower chance of unexpected data later in development leading to failures. We have also used our approach in eukaryotic settings, applying our modelling to identify oncology targets.

The company has 4 antimicrobial drug development projects (3 in collaboration with other groups), 2 oncology drug development projects and a CRO modelling, consulting and lab testing service (for which the income is used to fund drug development work).

We operate a CRO modelling, consulting and lab testing service (for which the income is used to fund drug development work). We are keen on supporting other groups working in the AMR space, where we can.

We are also looking to exploit our targets generated by our modelling using non-traditional approached. All our current programs are focussed on developing small molecule agents.